Thomas Gad, Chief Business Officer at Y-mAbs Therapeutics, Inc. (YMAB), sold 225,000 shares at $5.31 ($1.2M) on 2023-11-21, disclosed to the SEC on 2023-11-22.
Seasonal sale ($1.2M) by Chief Business Officer — this insider has traded YMAB in November in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.30 | 75,000 | $398K | 33.3% |
| 2 | $5.31 | 75,000 | $398K | 33.4% |
| 3 | $5.31 | 75,000 | $398K | 33.4% |
| Total | $5.31 avg | 225,000 | $1.2M | 100% |
| Filing → |
| YMAB | SELL | 2024-06-11 | $841K | — | Filing → |
| YMAB | SELL | 2024-05-23 | $396K | — | Filing → |
| YMAB | SELL | 2024-03-07 | $128K | — | Filing → |